MARKET

PTLA

PTLA

Portola Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.45
-0.68
-9.54%
After Hours: 6.45 0 0.00% 17:03 04/03 EDT
OPEN
7.07
PREV CLOSE
7.13
HIGH
7.17
LOW
6.41
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
37.95
52 WEEK LOW
5.31
MARKET CAP
503.62M
P/E (TTM)
-1.5898
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTLA stock price target is 20.33 with a high estimate of 31.00 and a low estimate of 14.00.

EPS

PTLA News

More
  • Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire · 4d ago
  • Portola Pharmaceuticals Option Alert: Apr 17 $7.5 Calls Sweep (3) near the Ask: 813 @ $0.3 vs 7860 OI; Earnings 5/6 Before Open [est] Ref=$6.48
  • Benzinga · 4d ago
  • Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)
  • PR Newswire · 03/18 21:11
  • Edited Transcript of PTLA earnings conference call or presentation 26-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/17 19:10

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About PTLA

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
More

Webull offers kinds of Portola Pharmaceuticals Inc stock information, including NASDAQ:PTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTLA stock news, and many more online research tools to help you make informed decisions.